お気に入りに追加
製品詳細
Synonyms
CD22, SIGLEC2, BL-CAM, SIGLEC-2, Siglec2, SIGLEC2FLJ22814
Source
APC-Labeled Human Siglec-2 Protein, His Tag (SI2-HA2H4) is produced via conjugation of APC to Human Siglec-2 Protein, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human Siglec-2 Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Asp 20 - Arg 687 (Accession # P20273-1).
Predicted N-terminus: Asp 20
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
Evaluation of CAR expression
FACS Analysis of Anti-Siglec-2 CAR Expression
5e5 of anti-CD22 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Siglec-2 Protein, His Tag (Cat. No. SI2-HA2H4) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
ProtocolFACS Analysis of Non-specific binding to PBMCs
5e5 of PBMCs were stained with APC-Labeled Human Siglec-2 Protein, His Tag (Cat. No. SI2-HA2H4) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Protocol
ユーザーレビュー コメントを投稿
バックグランド
最新の進展
医薬品開発の進捗- 英語名：
CD22
- カテゴリ：
- 市販の医薬品数：
2 詳細
- 治験医薬品数：
73 詳細
- 最新の開発ステージ：
Approved
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
